<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070810</url>
  </required_header>
  <id_info>
    <org_study_id>2008P000053</org_study_id>
    <nct_id>NCT01070810</nct_id>
  </id_info>
  <brief_title>Thiamine as a Metabolic Resuscitator in Septic Shock</brief_title>
  <official_title>Thiamine as a Metabolic Resuscitator in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <brief_summary>
    <textblock>
      The major goal of this project is to determine whether the use of thiamine in patients with
      septic shock will result in attenuation of lactic acidosis and a more rapid reversal of
      shock.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactate Level 24 Hours After the First Study Medication Dose</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Shock Reversal</measure>
    <time_frame>Hospital stay, average 2 weeks</time_frame>
    <description>Shock reversal was defined as &gt; 24 hours off all vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II Score at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>APACHE II (&quot;Acute Physiology and Chronic Health Evaluation II&quot;) is a severity-of-disease classification system; an integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lactate Level at 24 Hours in Patients With Baseline Thiamine Deficiency</measure>
    <time_frame>24 hours</time_frame>
    <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Dying Before Hospital Discharge in Patients With Baseline Thiamine Deficiency</measure>
    <time_frame>Hospital stay, average 2 weeks</time_frame>
    <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml D5W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg Thiamine in 50ml D5W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D5W</intervention_name>
    <description>Dextrose 5%</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiamine</intervention_name>
    <description>Thiamine 200mg in 50ml D5W</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 years old

          -  Suspected or confirmed source of infection

          -  Hypotension (systolic pressure &lt;90 mmHg) after a minimum 2 liter fluid bolus followed
             by vasopressor-dependence.

          -  Lactic Acidosis &gt; 3 mmol/dl

        Exclusion Criteria:

          -  Competing cause of lactic acidosis including: seizures within 3 hours of enrollment,
             use of linazolid metformin or anti-retrovirals at the time of enrollment, carbon
             monoxide or cyanide poisoning, highly suspected or known ischemic bowel, and known
             mitochondrial disorders

          -  Liver dysfunction specifically defined as AST or ALT elevation greater than 240

          -  Current Thiamine supplements or usage

          -  Competing indication for thiamine administration

          -  Cardiac Arrest

          -  DNR/DNI or comfort care status (DNR status in an intubated patient receiving full care
             is eligible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Donnino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>April 29, 2017</last_update_submitted>
  <last_update_submitted_qc>April 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Donnino</investigator_full_name>
    <investigator_title>Michael W. Donnino, MD</investigator_title>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>50 ml D5W
D5W: Dextrose 5%</description>
        </group>
        <group group_id="P2">
          <title>Thiamine</title>
          <description>200mg Thiamine in 50ml D5W
Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>50 ml D5W D5W: Dextrose 5%</description>
        </group>
        <group group_id="B2">
          <title>Thiamine</title>
          <description>200mg Thiamine in 50ml D5W Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="17"/>
                    <measurement group_id="B2" value="70" spread="14"/>
                    <measurement group_id="B3" value="67" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="7"/>
                    <measurement group_id="B2" value="29" spread="9"/>
                    <measurement group_id="B3" value="29" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lactate Level 24 Hours After the First Study Medication Dose</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 ml D5W
D5W: Dextrose 5%</description>
          </group>
          <group group_id="O2">
            <title>Thiamine</title>
            <description>200mg Thiamine in 50ml D5W
Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Lactate Level 24 Hours After the First Study Medication Dose</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.6" upper_limit="5.1"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.5" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Shock Reversal</title>
        <description>Shock reversal was defined as &gt; 24 hours off all vasopressors</description>
        <time_frame>Hospital stay, average 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 ml D5W
D5W: Dextrose 5%</description>
          </group>
          <group group_id="O2">
            <title>Thiamine</title>
            <description>200mg Thiamine in 50ml D5W
Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shock Reversal</title>
          <description>Shock reversal was defined as &gt; 24 hours off all vasopressors</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to shock reversal was complicated by a high incidence of death prior to the event. To account for this we classified death as a competing risk event and used the estimated cumulative incidence function (CIF) to illustrate the comparison of CIFs between the two treatment groups using the Fine-Gray competing risk model. We tested the subdistribution hazards of these two CIF functions and obtained the estimated hazard ratio with 95% confidence intervals.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>APACHE II Score at 24 Hours</title>
        <description>APACHE II (&quot;Acute Physiology and Chronic Health Evaluation II&quot;) is a severity-of-disease classification system; an integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death</description>
        <time_frame>24 hours</time_frame>
        <population>APACHE II was not available on 6 patients in each group at 24 hour mostly because of early death.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 ml D5W
D5W: Dextrose 5%</description>
          </group>
          <group group_id="O2">
            <title>Thiamine</title>
            <description>200mg Thiamine in 50ml D5W
Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
          </group>
        </group_list>
        <measure>
          <title>APACHE II Score at 24 Hours</title>
          <description>APACHE II (&quot;Acute Physiology and Chronic Health Evaluation II&quot;) is a severity-of-disease classification system; an integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death</description>
          <population>APACHE II was not available on 6 patients in each group at 24 hour mostly because of early death.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="10"/>
                    <measurement group_id="O2" value="23" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lactate Level at 24 Hours in Patients With Baseline Thiamine Deficiency</title>
        <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thiamine Deficient Received Thiamine</title>
            <description>Thiamine deficient (≤ 7 nmol/L) received 200mg Thiamine in 50ml D5W</description>
          </group>
          <group group_id="O2">
            <title>Thiamine Deficient, Received Placebo</title>
            <description>Thiamine deficient (≤ 7 nmol/L) received 50ml D5W</description>
          </group>
        </group_list>
        <measure>
          <title>Lactate Level at 24 Hours in Patients With Baseline Thiamine Deficiency</title>
          <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.4" upper_limit="2.5"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Dying Before Hospital Discharge in Patients With Baseline Thiamine Deficiency</title>
        <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
        <time_frame>Hospital stay, average 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thiamine Deficient Received Thiamine</title>
            <description>Thiamine deficient (≤ 7 nmol/L) received 200mg Thiamine in 50ml D5W</description>
          </group>
          <group group_id="O2">
            <title>Thiamine Deficient, Received Placebo</title>
            <description>Thiamine deficient (≤ 7 nmol/L) received 50ml D5W</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Dying Before Hospital Discharge in Patients With Baseline Thiamine Deficiency</title>
          <description>Baseline thiamine deficiency was defined as a baseline thiamine level of ≤ 7 nmol/L</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Hospital stay, average 2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>50 ml D5W D5W: Dextrose 5%</description>
        </group>
        <group group_id="E2">
          <title>Thiamine</title>
          <description>200mg Thiamine in 50ml D5W Thiamine: Thiamine 200mg in 50ml Dextrose 5%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael W Donnino</name_or_title>
      <organization>BIDMC</organization>
      <phone>617-754-2295</phone>
      <email>mdonnino@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

